Told You So....
Executive Summary
Protein Design Labs' announcement that it would discontinue trials of its antibody Zenapax against psoriasis was no surprise to SG Cowen analyst Bill Tanner, who'd reported at the end of February that clinicians involved in testing weren't very enthusiastic about it. Tanner may have been bloodied by criticism that his report was based on data that could not be statistically significant--but he remained unbowed. PDL's news reaffirmed his belief that analysts need to do fundamental research and talk to clinicians, instead of simply believing everything a company says.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.